Schedule 13G ownership disclosure

XILIO THERAPEUTICS INC

Security class unavailable · CUSIP: 98422T100

Event date: Unavailable

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
1,475,121
Percent of class
4.0000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001395064-24-000156
Form type
SC 13G/A
Filer
TAKEDA PHARMACEUTICAL CO LTD
CIK
CIK 1395064
Filed
Jul 31, 2024
Reporting period
—
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub